Results 11 to 20 of about 9,102 (179)

Allelic and Genotype Frequencies of CYP2B6∗2 (64C > T) and CYP2B6∗3 (777C > A) in Three Dominant Ethnicities of the Iranian Population

Genetics Research, 2023
Background. Cytochrome P450 complex plays a key role in drug metabolism. CYP2B6 has an essential part in Cytochrome P450 complex metabolism. This study aims to determine the allelic distribution of CYP2B6∗2 and CYP2B6∗3 in three main Iranian ethnicities:
Armin Khavandegar, Bahareh Tavakoli-Far, Sarina Ansari, Parisa Veis-Karami, Faezeh Ghasemi, Samira Sheibaninia, Roshanak Jazayeri, Massoud Houshmand   +7 more
doaj   +3 more sources

Insights into CYP2B6-mediated drug–drug interactions

Acta Pharmaceutica Sinica B, 2016
Mounting evidence demonstrates that CYP2B6 plays a much larger role in human drug metabolism than was previously believed. The discovery of multiple important substrates of CYP2B6 as well as polymorphic differences has sparked increasing interest in the ...
William D. Hedrich, Hazem E. Hassan, Hongbing Wang   +2 more
doaj   +3 more sources

PharmVar GeneFocus: CYP2B6 [PDF]

Clinical Pharmacology & Therapeutics, 2021
The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP2B6 gene. Genetic variation within the CYP2B6 gene locus impacts the metabolism or bioactivation of clinically important drugs. Of particular importance are efficacy and safety concerns regarding: efavirenz, which is used for the ...
Desta, Zeruesenay, El-Boraie, Ahmed, Gong, Li, Somogyi, Andrew A., Lauschke, Volker M., Dandara, Collet, Klein, Kathrin, Miller, Neil, Klein, Teri E., Tyndale, Rachel F., Whirl-Carrillo, Michelle, Gaedigk, Andrea   +11 more
openaire   +2 more sources

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications. [PDF]

Br J Clin Pharmacol
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Kiguba R, Ssesanga M, Pirmohamed M.
europepmc   +2 more sources

Molecular Characterization of CYP2B6 Substrates [PDF]

Current Drug Metabolism, 2008
CYP2B6 has not been as fully characterized at the molecular level as other members of the human cytochrome P450 family. As more widely used in vitro probes for characterizing the involvement of this enzyme in the metabolism of xenobiotics have become available, the number of molecules identified as CYP2B6 substrates has increased. In this study we have
Sean, Ekins, Manisha, Iyer, Matthew D, Krasowski, Evan D, Kharasch   +3 more
openaire   +2 more sources

Bioactivation of chlorpyrifos by CYP2B6 variants [PDF]

Xenobiotica, 2012
Chlorpyrifos (CPF), an organophosphorus (OP) pesticide, is bioactivated by cytochrome P450s (CYPs) to the active metabolite chlorpyrifos oxon (CPF-O). Given that human CYP2B6 has the highest intrinsic clearance (CL(int)) for CPF bioactivation, CYP2B6 polymorphisms may impact human susceptibility to CPF at real world environmental and occupational CPF ...
Alice L, Crane, Kathrin, Klein, James R, Olson   +2 more
openaire   +2 more sources

DEC1 negatively regulates CYP2B6 expression by binding to the CYP2B6 promoter region ascribed to IL-6-induced downregulation of CYP2B6 expression in HeLa cells

Xenobiotica, 2021
The cytochrome P450 superfamily (CYPs) is a group of metabolic enzymes involved in drug biotransformation/metabolism. It is the most important drug metabolic enzyme; however, its mechanism of action remains unclear.We investigated the expression of CYP2B6 in HeLa cells induced by interleukin-6 (IL-6) and explored the relationship between differentially
Xiaofei, Luan, Yi, Zhao, Na, Bu, Yue, Chen, Nan, Chen   +4 more
openaire   +2 more sources

Dataset of endo- and xenobiotic inhibition of CYP2B6: Comparison to CYP3A4

Data in Brief, 2022
Cytochrome P450 2B6 (CYP2B6) is a human enzyme important in chemical detoxification, steroid and fatty acid metabolism that is primarily hepatic. Therefore, induction or inhibition of CYP2B6 may perturb endo- and xenobiotic metabolism and cause adverse ...
Emily M. Olack, Melissa M. Heintz, William S. Baldwin   +2 more
doaj   +1 more source

Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo [PDF]

Drug Metabolism and Disposition, 2012
The mechanism by which CYP2B6*6 allele alters drug metabolism in vitro and in vivo is not fully understood. To test the hypothesis that altered substrate binding and/or catalytic properties contribute to its functional consequences, efavirenz 8-hydroxylation and bupropion 4-hydroxylation were determined in CYP2B6.1 and CYP2B6.6 proteins expressed ...
Cong, Xu, Evan T, Ogburn, Yingying, Guo, Zeruesenay, Desta   +3 more
openaire   +2 more sources

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network

Pharmaceutics, 2021
The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug–drug interaction (DDI) studies.
Fatima Zahra Marok, Laura Maria Fuhr, Nina Hanke, Dominik Selzer, Thorsten Lehr   +4 more
doaj   +1 more source